Compare Medpace Holdings Inc (MEDP) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Symbotic Inc — how do they compare? Medpace Holdings Inc trades at $616.5 (market cap $16.82B), while Symbotic Inc trades at $42.3 (market cap $5.46B). The key difference: Medpace Holdings Inc is far larger — about 3.1× Symbotic Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Symbotic Inc for 23 Days on average.
| MEDP | SYM | |
|---|---|---|
Market Cap | $16.82B | $5.46B |
Volume | 223,093 | 1,965,805 |
Sector | Health | Industrials |
52-Week High | $630.19 | $87.30 |
52-Week Low | $393.42 | $38.22 |
Typical Hold Time | 14 Days | 23 Days |
Enterprise Value | $16.44B | $3.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
SYM trades at $42.73, down 1.34% today, with bearish technical signals dominating. The stock shows mixed fundamentals with strong revenue growth projected ($2.6B in 2026) but negative 2025 net income of -$16.94M. Recent earnings show two misses against expectations, though Q4 2025 beat estimates. Analyst consensus remains positive with 61% buy ratings and a $60.33 price target, representing 41% upside potential from current levels.
The outlook balances growth potential against execution risks. SYM's $22.5B backlog and expanding AI/robotics market position offer substantial upside, but customer concentration (85% Walmart revenue) and recent earnings misses create near-term uncertainty. Technical indicators suggest caution with bearish moving average signals, though oversold conditions may present entry opportunities for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
